Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ Launching 3 Exhilarating 7-night Itineraries From Barcelona With Overnights in Ibiza
19.11.2019 17:02:00 EET | Business Wire | Press release
Virgin Voyages, the new lifestyle brand shaking up the travel industry, announced their second ship will be called ‘Valiant Lady’ and that she will sail 7-night Mediterranean itineraries out of Barcelona, Spain when she debuts in May 2021. Bookings for the three feature itineraries, that all offer overnight and late-night stops across some of the hottest destinations in France, Italy and Spain, will open December 19, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005362/en/
Virgin Voyages Sets Sights on the Med for Second Ship ‘Valiant Lady’ (Graphic: Business Wire)
“We are thrilled to unveil the name of our second ship - Valiant Lady - and to deliver on our commitment to offer travelers a sea change in how they can experience cruising in this fantastic part of the world. Our Sailors will fall in love with the places we go and the moments and memories they will be able to create on our gorgeous ship. After all, there is no better way to sail the seven seas than doing it the Virgin way,” said Tom McAlpin, CEO of Virgin Voyages.
2021 Summers on the Med with a home in Barcelona
Valiant Lady will dock just steps from Las Ramblas at the World Trade Center Barcelona, positioning Sailors as close to the heart of this stunning departure-port-city as possible. This prime location, usually reserved by luxury liners and mega-yachts, gives walking access to the dynamic and diverse neighborhoods of Poble Sec, el Raval, Barri Gotic, Port Vell and the famed urban beach of La Barceloneta. With a weekly Sunday sail away, Sailors will enjoy extra time in Barcelona and be able to take advantage of many different flight options. Virgin Voyages is partnering with Global Ports Holding, the world’s leading independent cruise port operator, to prepare for Valiant Lady’s arrival in early summer 2021.
Open for bookings December 2019, 7 night sailings start May 2021 and feature an overnight in Ibiza
The Med, home to some of the world’s best beach clubs, cultural experiences, restorative spas, yacht clubs and nightlife, is a perfect choice for Virgin Voyages. Valiant Lady will sail 3 different itineraries with truly breathtaking ports of call.
- Itinerary 1 includes the exotic delights of Barcelona, Ibiza, Monte Carlo, Marseille and Olbia
- Itinerary 2 includes a fantastic sampling of the Med featuring Barcelona, Ibiza, Toulon, Ajaccio, Marina di Carrara and Cagliari
- Itinerary 3 is a mostly Spanish immersion, stopping by Barcelona, Ibiza, Palma de Mallorca, Malaga and the British port of Gibraltar
Hearing Sailor and First Mates (travel partners) requests for later stays in ports, Virgin has delivered this on every itinerary. This means Sailors have the flexibility to make the most of their time in port and take in all that these destinations have to offer. Of particular note, every sailing features a Friday overnight stay in Ibiza, one of the most stunning and thrilling Balearic Islands. Whether it’s a blissed out beach club, a bohemian market, a serene spa, watching the stunning sunsets, or a late night out, there is no comparable place that offers the variety and style of this ultimate destination.
Introducing ‘Valiant Lady’
Virgin Voyages also revealed that the name ‘Valiant Lady’ was inspired by the Latin word valere and from the French origin, vaillant, meaning “bold”, “strong”, and “courageous." While historically, the image of women only graced the bows of ships to bring protection to a vessel, ‘Valiant Lady’ embodies the idea that women design, captain, lead and champion change in the maritime industry.
The Scarlet Lady’s sister ship ‘Valiant Lady’ will continue Virgin Voyages’ ‘Scarlet Squad’ program aimed at recruiting, supporting and mentoring female shipboard talent, and growing opportunities to access leadership roles in onboard areas such as marine, technical and hotel management that statistically show low numbers of female leadership.
All Virgin Voyages ships have been designed by a leading creative collective who are the brains behind some of the world’s most loved boutique hotel brands. The collective includes names like Design Research Studio (Tom Dixon), Roman & Williams and Concrete Amsterdam who have all been inspired by the brand’s design concept- the Modern Romance of Sailing and Mission to Redefine the Experience of a Vacation at Sea.
Future Sailors, First Mates and travel advisors are invited to check out Virgin Voyages by visiting www.virginvoyages.com or following @virginvoyages on Instagram, Facebook, Twitter or LinkedIn.
ABOUT VIRGIN VOYAGES
Virgin Voyages is a global lifestyle brand committed to creating the world’s most irresistible holidays. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and Europe. Virgin Voyages’ ships are designed to reflect a super yacht’s sleek luxury, featuring spaces designed by some of the top names in contemporary interiors. An Adult-by-Design sanctuary, the ships offer a dose of Vitamin Sea with well-being activated through a mix of high-energy moments coupled with relaxation and rejuvenation. Scarlet Lady will also feature never before seen entertainment and 20+ world-class intimate eateries on board. Virgin Voyages offers incredible value for its sailors with all restaurants, group fitness classes, soft drinks, and many more Virgin surprises included within the voyage fare. Scarlet Lady will sail from Miami to the Caribbean all year round from March 2020 and Valiant Lady will sail the Mediterranean from May 2021. The fleet's ships host more than 2,770 sailors and 1,160 amazing crew from around the world. Keep watch on virginvoyages.com for more updates.
FOLLOW VIRGIN VOYAGES:
Instagram: @virginvoyages
Facebook: @virginvoyages
Twitter: @virginvoyages
LinkedIn: Virgin Voyages
YouTube: Virgin Voyages
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005362/en/
Contact information
ALISON BROD MARKETING + COMMUNICATIONS
Virgin@alisonbrodmc.com
Virgin Voyages
Michelle Estevam, media@virginvoyages.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom